Autosomal Recessive Cutis Laxa Type 2A

1. Disease Information

Overview. ARCL2A is a rare inherited connective-tissue disorder characterized by loose, redundant, inelastic, wrinkled skin (cutis laxa) together with a variable spectrum of skeletal, neurodevelopmental, craniofacial, and ophthalmologic abnormalities. It is simultaneously classified as a congenital disorder of glycosylation (CDG type II) because the underlying V-ATPase defect impairs both N-linked and O-linked glycan biosynthesis in the Golgi.

Key identifiers.

Synonyms / alternative names. ARCL2A; ATP6V0A2-related cutis laxa; ATP6V0A2-CDG; cutis laxa type IIA; wrinkly skin syndrome (WSS, considered a phenotypic variant of the same disorder). The clinical continuum between severe cutis laxa and milder wrinkly skin syndrome reflects allelic variation at the same locus (PMID: 19401719).

Source of information. The characterization here is derived from aggregated disease-level resources — OMIM, systematic reviews, cohort studies, and case reports in the primary literature — rather than individual patient EHR data.

2. Etiology

Primary cause — genetic. ARCL2A is caused by biallelic (homozygous or compound heterozygous) loss-of-function variants in ATP6V0A2, which encodes the a2 subunit of the V-type H⁺-ATPase (Finding F001). Kornak et al. first identified these loss-of-function mutations in multiple families with autosomal recessive cutis laxa type II / wrinkly skin syndrome:

"We identified loss-of-function mutations in ATP6V0A2, encoding the a2 subunit of the V-type H+ ATPase, in several families with autosomal recessive cutis laxa type II or wrinkly skin syndrome." — PMID: 18157129

Genetic risk factors. The disease is monogenic and fully genetically determined by ATP6V0A2 genotype; there are no known susceptibility loci beyond the causal gene. The dominant variant class is predicted null alleles. In the Morlino 2021 systematic review, ~78.3% of known variants were predicted null (nonsense, frameshift, splice), with 11 missense and 2 noncanonical splice variants (Finding F001):

"About 78.3% of known variants were predicted null alleles, while 11 were missense and 2 affected noncanonical splice sites." — PMID: 33369135

Environmental risk factors. None are established. ARCL2A is a Mendelian disorder; parental consanguinity is the principal epidemiological risk context because it increases the likelihood of homozygosity for rare recessive alleles (Finding F006). There are no known toxic, occupational, infectious, or lifestyle triggers.

Protective factors. No genetic or environmental protective factors have been defined. However, the missense variant p.P87L is associated with unusually mild disease, indicating that residual protein function attenuates severity (Finding F003).

Gene–environment interactions. None documented. The disease is essentially environment-independent; phenotypic variability appears driven by genotype (null vs. residual-function alleles) and developmental timing rather than gene–environment interaction.

3. Phenotypes

ARCL2A spans a continuum from a severe phenotype with skin, skeletal, and neurological involvement to an attenuated adult phenotype dominated by cutaneous features (Findings F004, F008). A central discriminator is age at ascertainment: earlier presentation correlates with more severe systemic involvement.

"Age at ascertainment appeared as the unique phenotypic discriminator with earlier age more commonly associated with facial dysmorphism (p .02), high/cleft palate (p .005), intellectual disability/global developmental delay (p .013), and seizures (p .024)." — PMID: 33369135

Neurological features are a distinguishing element of ARCL2A within the cutis laxa family. Epilepsy is the most common neurological finding in ATP6V0A2 defects, and gyration/migration abnormalities and abnormal glycosylation are mostly associated with ATP6V0A2 mutations (Finding F004):

"Epilepsy was most common in ATP6V0A2 defects." — PMID: 23963297

Ocular involvement (Finding F005) is increasingly recognized. In a Ghent cohort of 13 genetically confirmed cutis laxa patients (4 with ATP6V0A2), reduced visual acuity was detected solely in the ATP6V0A2 subtype:

"Reduced corrected visual acuity was detected solely in patients with the ATP6V0A2 subtype. Three (23.1%) cases of keratoconus were detected in the cohort. All 4 patients with ATP6V0A2-related CL had prominent corneal tomographic abnormalities, with either high-grade astigmatism or pronounced corneal flattening and thinning." — PMID: 40043299

Retinal involvement is documented in a case with macular and chorioretinal scarring:

"Funduscopic examination showed a round macular scar lesion in the right eye macula and a chorioretinal scar superonasally in the left eye." — PMID: 36728588

Quality of life. Per-phenotype QOL data (EQ-5D/SF-36) are not available for this rare disease. Functionally, the greatest burdens derive from neurodevelopmental impairment (in severe/early-onset cases), reduced visual acuity (ATP6V0A2-specific ocular disease), and the cosmetic/psychosocial impact of skin laxity. The attenuated phenotype, dominated by non-life-threatening cutaneous features, is compatible with a relatively favorable functional outcome (Finding F008).

4. Genetic / Molecular Information

Causal gene. ATP6V0A2 (chr 12q24.31), encoding the a2 subunit of the trans-Golgi V-type H⁺-ATPase (Finding F001).

Pathogenic variant spectrum. - Variant classes: predominantly null alleles. ~78.3% predicted null (nonsense, frameshift, canonical splice), 11 missense, 2 noncanonical splice (PMID: 33369135). - Representative variants: recurrent 380-bp exon 16 deletion c.1936-147_2055+113del (founder allele, Türkiye); c.235del (p.Leu79Phefs*13); c.1977_1980del (p.Val660LeufsTer23, Pakistani family); missense p.P87L (unusually mild disease); multiple novel intronic/splice variants across Iranian, Han-Chinese, and other families (Findings F003, F006). - Functional consequence: loss of function. Premature-stop mutations reduce ATP6V0A2 mRNA via nonsense-mediated decay; the mutant protein is lost in patient dermal fibroblasts (Finding F003):

"Premature stop codon mutations led to decreased ATP6V0A2 mRNA levels by destabilizing the mutant mRNA via the nonsense-mediated decay pathway." — PMID: 19321599

• Origin: germline (biallelic). No somatic contribution.
• Allele frequency: individually rare/private; most alleles are population-specific and often observed in consanguineous families.

Modifier genes / epigenetics. No formal modifier genes or epigenetic mechanisms have been established for ARCL2A. Phenotypic variability is largely attributable to allele type (null vs residual function) and developmental timing.

Chromosomal abnormalities. ARCL2A is not caused by large-scale aneuploidy or translocations, though intragenic structural deletions (e.g., the recurrent exon 16 deletion) are an important variant class (Finding F006).

5. Environmental Information

Environmental factors, lifestyle factors, and infectious agents are not applicable. ARCL2A is a monogenic recessive disorder with no established environmental, toxic, occupational, dietary, or infectious contributors. The only relevant non-molecular epidemiological factor is consanguinity, which increases the probability of biallelic inheritance rather than acting as a disease-causing exposure.

6. Mechanism / Pathophysiology

Causal chain

Biallelic LOF in ATP6V0A2
│  (NMD of null alleles → loss of V0a2 protein)
▼
Loss of trans-Golgi V-ATPase a2 subunit
│
▼
Elevated Golgi luminal pH (loss of proton pumping)
│
├─► Combined N-/O-glycosylation defect (CDG-II)  ──► serum transferrin + apoC-III abnormality
│
├─► Golgi fragmentation + delayed BFA-induced retrograde transport
│            │
│            ▼
│     Impaired tropoelastin secretion → intracellular TE retention/aggregation
│            │
│            ▼
│     ↓ extracellular mature elastin deposition + ↑ apoptosis ──► CUTIS LAXA
│
├─► Elevated TGF-β1 signaling ──► dysregulated ECM homeostasis
│
└─► Aberrant cortical neuron migration ──► NEURODEVELOPMENTAL / EPILEPSY phenotype

Molecular and cellular detail

Golgi V-ATPase dysfunction. ATP6V0A2 localizes to the Golgi apparatus, where the V-ATPase acidifies the lumen. Loss of V0a2 elevates Golgi pH. Kopp et al. (2024) directly demonstrated in Atp6v0a2 knockout mice that this pH elevation correlates with tissue-specific glycosylation changes and aberrant cortical neuron migration (Findings F002, F007):

"Loss-of-function variants in ATP6V0A2, encoding the trans Golgi V-ATPase subunit V0a2, cause wrinkly skin syndrome (WSS), a connective tissue disorder with glycosylation defects and aberrant cortical neuron migration." — PMID: 39680136

Impaired trafficking and TGF-β signaling. Patient and knockdown cells show delayed brefeldin-A-induced Golgi collapse/retrograde transport, a fragmented Golgi, and elevated TGF-β signaling (Finding F002):

"Investigation of brefeldin A-induced Golgi collapse in dermal fibroblasts as well as in HeLa cells deficient for ATP6V0A2 revealed a delay" — PMID: 22773132

"fibroblasts from patients with ATP6V0A2 mutations displayed elevated TGF-β signalling and increased TGF-β1 levels in the supernatant" — PMID: 22773132

Tropoelastin secretion block (the direct cause of cutis laxa). Hucthagowder et al. (2009) showed in a 17-patient cohort that ATP6V0A2 loss produces distended Golgi cisternae and abnormal lysosomes/multivesicular bodies, with tropoelastin accumulating in the Golgi and forming abnormal intracellular/extracellular aggregates (Finding F003):

"Immunostaining of ARCL2 cells showed the accumulation of tropoelastin (TE) in the Golgi and in large, abnormal intracellular and extracellular aggregates. Pulse-chase studies confirmed impaired secretion and increased intracellular retention of TE, and insoluble elastin assays showed significantly reduced extracellular deposition of mature elastin." — PMID: 19321599

Notably, fibrillin-1 microfibril assembly and lysyl oxidase activity were normal, localizing the defect specifically to tropoelastin trafficking rather than downstream elastin crosslinking. TUNEL assays showed increased apoptosis, contributing to tissue fragility.

Ontology anchors

• Biological processes (GO): protein glycosylation (GO:0006486); Golgi lumen acidification / regulation of pH (GO:0007035); retrograde transport, Golgi to ER (GO:0006890); extracellular matrix organization (GO:0030198); TGF-β receptor signaling (GO:0007179); apoptotic process (GO:0006915); neuron migration (GO:0001764).
• Cellular components (GO): Golgi membrane (GO:0000139); trans-Golgi network (GO:0005802); proton-transporting V-type ATPase complex (GO:0033176).
• Cell types (CL): dermal fibroblast (CL:0002620); cortical neuron / migrating neuron.
• Chemical entities (CHEBI): proton (CHEBI:24636); ATP (CHEBI:30616); N-glycan / O-glycan; sialic acid (CHEBI:26667).

7. Anatomical Structures Affected

The primary lesion is at the subcellular level (Golgi), propagating to a connective-tissue phenotype (dermis) and a neuronal migration phenotype (cortex).

8. Temporal Development

Onset. Congenital / neonatal. Skin laxity and dysmorphism are typically present from birth; large fontanelles and developmental concerns emerge in infancy (Finding F004).

Progression. ARCL2A is generally non-progressive to attenuating. Systemic features (facial dysmorphism, high/cleft palate, intellectual disability, seizures) are enriched at earlier ages, and the phenotype shifts over time toward one dominated by cutaneous involvement, with skin laxity tending to attenuate (Findings F004, F008):

"This work confirmed the existence of an attenuated phenotype associated with ATP6V0A2 biallelic variants and offers an updated critique to the clinical and molecular variability of ARCL2A." — PMID: 33369135

"The associated clinical spectrum subsequently expanded to a less severe phenotype dominated by cutaneous involvement." — PMID: 33369135

Course and duration. Chronic, lifelong genetic disorder. Rare severe congenital forms of ARCL type 2 can involve life-threatening neonatal pulmonary emphysema, but this is not typical of ARCL2A (Finding F008). A subset with a novel c.235del showed severe neurological regression, indicating variability at the severe end (Finding F006).

Critical period. The prenatal/perinatal window of cortical neuronal migration is the key period of vulnerability for the neurological phenotype (Finding F007).

9. Inheritance and Population

Inheritance pattern. Autosomal recessive; biallelic loss of function (Findings F001, F006).

Epidemiology. ARCL2A is very rare; precise prevalence/incidence figures are not established in registries. It occurs worldwide and is enriched in consanguineous populations (Finding F006).

Founder effects and geographic distribution. A recurrent homozygous 380-bp exon 16 deletion with a shared haplotype was identified in southeastern Türkiye, indicating a founder effect (Finding F006):

"Nine individuals carried a recurrent homozygous 380 bp deletion spanning exon 16 (c.1936-147_2055+113del). ... Haplotype analysis revealed shared homozygous regions in three cases, suggesting a founder effect." — PMID: 41732832

ARCL2A has been reported in Turkish, Pakistani, Iranian, Han-Chinese, Italian, and other families, frequently with documented parental consanguinity.

"Autosomal recessive cutis laxa type 2A (ARCL2A; OMIM: 219200) is characterized by neurovegetative, developmental and progeroid elastic skin anomalies. It is caused by biallelic variation in ATPase, H..." — PMID: 37119015

Penetrance / expressivity. Penetrance of biallelic null genotypes is effectively complete; expressivity is highly variable and age-dependent. No specific genotype–phenotype correlation was identified in the systematic review, aside from the observation that residual-function missense alleles (e.g., p.P87L) can be milder (Findings F003, F004).

Sex ratio / anticipation / mosaicism. No sex bias is expected (autosomal). Genetic anticipation is not applicable (no repeat expansion). Germline mosaicism is not a recognized feature.

Carrier frequency. Not formally established; expected to be low outside founder populations.

10. Diagnostics

Biochemical screening (first-line gateway)

ARCL2A is a CDG-II with a combined N-/O-glycosylation defect. The validated first-line biochemical screen is combined plasma transferrin isoelectric focusing (TIEF) plus apolipoprotein C-III (apoC-III) isoelectric focusing (Finding F010). Transferrin IEF distinguishes N-glycan assembly (type 1) from processing (type 2/CDG-II) defects; apoC-III IEF detects core-1 mucin-type O-glycan defects. Together they detect the combined defect characteristic of ATP6V0A2 deficiency:

"Plasma apoC-III IEF is complementary to transferrin isofocusing. In conjunction both tests identify biosynthesis defects in N-glycan and mucin-type core 1 O-glycan biosynthesis." — PMID: 17170056

"the CDG-IIx patients could be further subdivided into six biochemical subgroups" — PMID: 16037491

ATP6V0A2 deficiency produces a CDG-II transferrin pattern together with an abnormal (hyposialylated) apoC-III O-glycan profile.

Genetic testing (definitive)

Molecular confirmation is required (Finding F011). Recommended approaches: - Single-gene sequencing of ATP6V0A2 (with deletion/duplication analysis to detect intragenic structural variants such as the exon 16 deletion). - Gene panels for cutis laxa / connective-tissue disorders (should include ATP6V0A2, ATP6V1A, ATP6V1E1, PYCR1, ALDH18A1, ELN, FBLN4/5). - Whole-exome / whole-genome sequencing for phenotypic overlap cases; WGS improves detection of deep intronic/splice and structural variants. - Minigene assays help classify novel splice variants.

Histopathology

Skin biopsy shows sparse/fragmented dermal elastic fibers (orcein staining). Ultrastructure and cell studies show distended Golgi cisternae, abnormal lysosomes/multivesicular bodies, and intracellular tropoelastin aggregates.

Differential diagnosis

Because cutis laxa syndromes share overlapping features, molecular diagnosis is essential (Finding F011):

"Thus, molecular diagnosis is the only way to resolve these phenotypically similar conditions." — PMID: 26538727

Key differentials and their discriminators:

"Corpus callosum dysgenesis was associated with PYCR1 and ALDH18A1 mutations. Dystonic posturing was discriminatory for PYCR1 and ALDH18A1 defects." — PMID: 23963297

Screening

Carrier and cascade screening in affected families is appropriate; in founder populations (e.g., southeastern Türkiye) targeted testing for the recurrent allele is efficient. Prenatal/preimplantation genetic diagnosis is feasible once the familial variants are known.

11. Outcome / Prognosis

Overall prognosis is generally favorable, especially in the attenuated phenotype dominated by non-life-threatening cutaneous features (Finding F008). Skin laxity and dysmorphism tend to attenuate with age.

• Survival / mortality: No systematic survival data; the attenuated form is compatible with normal or near-normal life expectancy. The severe congenital end of the broader ARCL type 2 spectrum can rarely involve life-threatening neonatal pulmonary emphysema.
• Morbidity / function: Determined by neurodevelopmental impairment in severe/early cases and by ATP6V0A2-specific ocular disease (reduced visual acuity, keratoconus, corneal thinning). Skeletal features (joint laxity, hip dislocation) contribute to orthopedic morbidity.
• Prognostic factors: Earlier age at ascertainment predicts more severe systemic (facial, palatal, neurodevelopmental, seizure) involvement; residual-function alleles (e.g., missense p.P87L) predict milder disease (Findings F003, F004).

"This work confirmed the existence of an attenuated phenotype associated with ATP6V0A2 biallelic variants..." — PMID: 33369135

12. Treatment

There is no disease-specific or curative therapy for the underlying V-ATPase/glycosylation defect (Finding F008). Management is symptomatic, supportive, and multidisciplinary:

• Dermatologic: cosmetic/reconstructive plastic surgery for redundant skin where indicated; sun protection and skin care.
• Neurologic / developmental: anti-seizure medication for epilepsy; early developmental intervention, physical/occupational/speech therapy for developmental delay and intellectual disability.
• Orthopedic: management of joint laxity, hip dislocation, and skeletal anomalies; physiotherapy.
• Ophthalmologic: surveillance and correction for high astigmatism/keratoconus (spectacles, rigid contact lenses, corneal cross-linking where appropriate); management of retinal/macular lesions.
• Craniofacial: cleft/high-palate repair and feeding support as needed.

Pharmacogenomics, gene therapy, cell therapy, RNA-based therapy, targeted therapy, and immunotherapy are not established for ARCL2A. The Atp6v0a2 knockout mouse provides a platform for future mechanism-based intervention studies. NCIT clinical-intervention terms would map primarily to supportive/rehabilitative and reconstructive-surgical categories (e.g., NCIT:C15329 Rehabilitation Therapy; NCIT:C15329-adjacent supportive-care terms; NCIT:C15265 Reconstructive Surgery).

13. Prevention

Because ARCL2A is a Mendelian recessive disorder with no environmental cause, prevention is genetic and reproductive, not lifestyle-based:

• Genetic counseling for at-risk families, especially those with consanguinity (25% recurrence risk per pregnancy for two carrier parents).
• Carrier and cascade screening of relatives once the familial ATP6V0A2 variants are identified; efficient in founder populations via targeted testing (Finding F006).
• Prenatal diagnosis / preimplantation genetic testing for known familial variants.
• Tertiary prevention: ophthalmologic, neurologic, orthopedic, and developmental surveillance to prevent complications and optimize function.

Primary prevention by vaccination, behavioral change, or environmental modification is not applicable.

14. Other Species / Natural Disease

• Taxonomy / orthologs: The mouse ortholog Atp6v0a2 is well characterized (see §15). Orthologs of the V-ATPase a2 subunit are broadly conserved across vertebrates, reflecting the essential housekeeping role of Golgi acidification.
• Natural disease in other species: No well-documented naturally occurring ARCL2A-equivalent disease in companion animals or wildlife is described in the reviewed literature.
• Comparative biology / conservation: The Golgi V-ATPase → glycosylation → connective-tissue/neuronal-migration axis is evolutionarily conserved, supporting cross-species modeling of the mechanism (Finding F007).
• Transmission / zoonosis: Not applicable (non-infectious genetic disorder).

15. Model Organisms

Primary model — Atp6v0a2 knockout mouse (Kopp et al., 2024). This mammalian genetic knockout recapitulates the core disease mechanism and several key phenotypes (Finding F007):

"Loss-of-function variants in ATP6V0A2, encoding the trans Golgi V-ATPase subunit V0a2, cause wrinkly skin syndrome (WSS), a connective tissue disorder with glycosylation defects and aberrant cortical neuron migration." — PMID: 39680136

Cellular / in-vitro models. Patient dermal fibroblasts and ATP6V0A2-knockdown HeLa cells are extensively used and reproduce Golgi fragmentation, delayed BFA-induced retrograde transport, tropoelastin retention, elevated TGF-β, and increased apoptosis (Findings F002, F003).

Phenotype recapitulation and limitations. The mouse faithfully models the Golgi-pH, glycosylation, and neuronal-migration axis but adds a reproductive phenotype (globozoospermia) not emphasized in humans, and the fidelity of the cutaneous phenotype requires further characterization. Cellular models capture the trafficking/secretion defect but not the whole-organism, age-dependent attenuation observed clinically.

Resources. MGI (mouse), plus patient-derived fibroblast lines and HeLa knockdown systems reported in the primary literature.

Mechanistic Model / Interpretation

ARCL2A is best understood as a single primary lesion (loss of Golgi V-ATPase a2 subunit) producing a fan of downstream consequences through one shared node — elevated Golgi luminal pH. Two branches dominate the clinical picture:

1. Secretory/ECM branch → skin. Elevated pH and impaired trafficking cause tropoelastin to be retained in a fragmented Golgi, reducing extracellular mature elastin and increasing fibroblast apoptosis. This directly yields cutis laxa. Elevated TGF-β signaling further dysregulates ECM homeostasis. Crucially, downstream elastin crosslinking machinery (lysyl oxidase) and microfibril scaffolding (fibrillin-1) are intact, so the defect is specifically a secretion/deposition problem, not a crosslinking or scaffold problem.

2. Glycosylation/neurodevelopmental branch → brain and biochemistry. The same pH elevation impairs both N- and O-glycosylation (giving the diagnostic transferrin + apoC-III signature) and disrupts cortical neuron migration, explaining developmental delay, intellectual disability, epilepsy, and gyration abnormalities.

Upstream vs downstream: Golgi de-acidification is the upstream hub; glycosylation defects, trafficking delay, tropoelastin retention, TGF-β elevation, apoptosis, and neuronal migration failure are parallel downstream effects. The age-dependent attenuation of the skin phenotype, contrasted with the earlier-limited window for cortical migration, explains why systemic/neurological features cluster at younger ages while older patients present predominantly with cutaneous findings.

ARCL2A sits within a coherent V-ATPase/Golgi cutis-laxa family — ATP6V0A2 (ARCL2A), ATP6V1A (ARCL2D), ATP6V1E1 (ARCL2C) — that shares Golgi fragmentation, delayed retrograde transport, and glycosylation abnormalities, plus the mitochondrial proline-cycle disorders PYCR1 (ARCL2B) and ALDH18A1 (ARCL3/de Barsy). This unifying pathomechanism (Finding F009) is why molecular confirmation is indispensable:

"One group of these metabolic cutis laxa conditions is autosomal recessive cutis laxa type 2 caused by defects in v-ATPase components or the mitochondrial proline cycle." — PMID: 33320377

"a fragmented Golgi compartment, a delayed Brefeldin A-induced retrograde transport and glycosylation abnormalities were present in fibroblasts" — PMID: 33320377

Evidence Base

Evidence source types: human clinical (cohorts, case reports, systematic review), in vitro (patient fibroblasts, HeLa knockdown, pulse-chase, TUNEL), and model organism (Atp6v0a2 KO mouse). The strongest, most convergent evidence supports the causal gene, the Golgi-pH/glycosylation mechanism, the tropoelastin-secretion basis of cutis laxa, and the diagnostic strategy.

Limitations and Knowledge Gaps

1. No investigation-specific dataset was analyzed. This report synthesizes published literature; no primary omics data (transcriptomics, proteomics, metabolomics) were generated or re-analyzed for this job. Detailed molecular-profiling sections (single-cell, spatial, multi-omics, CRISPR screens) are largely unpopulated because such studies for ARCL2A are scarce.
2. Epidemiology is imprecise. Formal prevalence/incidence and carrier-frequency estimates are unavailable; the disease is known chiefly through small cohorts and case reports.
3. Genotype–phenotype correlation is limited. No specific correlation beyond the null-vs-residual-function distinction has been established; phenotypic variability is incompletely explained.
4. Quality-of-life and natural-history data are sparse. No standardized QOL instruments have been applied; long-term outcome data rely on cross-sectional ascertainment.
5. Modifier genes and epigenetics are unexplored. No modifier loci or epigenetic mechanisms have been defined.
6. Model fidelity for skin is uncertain. The Atp6v0a2 KO mouse robustly models glycosylation and neuronal migration but the cutaneous phenotype and its age-dependent attenuation require deeper characterization.

Proposed Follow-up Experiments / Actions

1. Natural-history and registry study to quantify prevalence, age-dependent progression/attenuation, and standardized QOL (e.g., PROMIS, pediatric instruments) across the ARCL2A spectrum.
2. Genotype–phenotype meta-analysis integrating all reported ATP6V0A2 variants (null vs. residual-function missense/splice) with quantitative phenotype scoring to test whether residual protein function predicts severity.
3. Single-cell and spatial transcriptomics of patient skin and iPSC-derived cortical organoids to map cell-type-specific consequences of Golgi de-acidification on tropoelastin secretion and neuronal migration.
4. Targeted glycomics (mass-spectrometry N-/O-glycan profiling) to refine the diagnostic biochemical signature beyond IEF and evaluate it as a quantitative biomarker.
5. Mechanism-based therapeutic screening using patient fibroblasts and the Atp6v0a2 KO mouse — e.g., agents that restore Golgi pH homeostasis, enhance tropoelastin secretion, or modulate TGF-β signaling.
6. Founder-population carrier screening programs (e.g., southeastern Türkiye) leveraging the recurrent exon 16 deletion for cost-effective cascade testing and reproductive counseling.
7. Systematic ophthalmologic surveillance protocol validation, given the ATP6V0A2-specific corneal/retinal burden identified in recent cohorts.

Report compiled from 11 confirmed findings and 30 reviewed papers over a multi-iteration autonomous investigation. Evidence types span human clinical, in vitro, and model-organism studies. Ontology suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) are provided throughout to support knowledge-base ingestion.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0018163 (2 mentions) - the report calls it "MONDO"; MONDO calls it autosomal recessive cutis laxa type 2A

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0006486 (obsolete protein glycosylation) (1 mention) - replaced by GO:0009101

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0002269 (1 mention) - the report calls it "Abnormal cortical gyration"; HP calls it Abnormality of neuronal migration, and lists "Abnormal neuronal migration" among its other names